Product ID:SODIUM IODIDE I 131 ORAL THERAPEUTIC SOLUTION
MSDS Date:01/01/1995
FSC:6505
NIIN:00N091105
Status Code:A
MSDS Number: CJHMK

MALLINCKRODT MEDICAL, INC

2703 WAGNER PLACE
MARYLAND HEIGHTS, MO 63043-3421
US

Emergency Phone: 314-770-7800

Info Phone: 314-770-7800

Cage: 2A916

MALLINCKRODT DIAGNOSTICS

MARYLAND HEIGHTS, MO 63043-3421 US

Telephone: 314-344-3800

Cage: 2A916

SODIUM IODIDE-131

CAS: 7790-26-3

EDTA DISODIUM SALT

CAS: 139-33-3

RTECS: AH4375000

SODIUM PHOSPHATE, DIBASIC

CAS: 7558-79-4

RTECS: WC4500000

EPA Report Quantity: 5000 LBS

DOT Report Quantity: 5000 LBS

SODIUM BISULFITE

CAS: 7631-90-5

RTECS: VZ2000000

ACGIH TLV: 5 MG/M3

EPA Report Quantity: 5000 LBS

DOT Report Quantity: 5000 LBS

WATER

CAS: 7732-18-5

RTECS: ZC0110000

Routes of Entry: Inhalation:YES Skin:YES Ingestion:YES
Reports of Carcinogenicity:NTP:NO IARC:NO OSHA:NO
Health Hazards Acute and Chronic:THE HAZARDOUS, NON-READIOACTIVE
INGREDS IN SODIUM IODIDE I 131 ORAL THERAPEUTIC SOLN ARE SKIN & EYE
IRRITANTS, BUT DUE TO SM QTYS PRESENT IN EACH CNTNR, NO ADVERSE
EFTS ARE EXPECTED TO OCCUR FROM THES E COMPONENTS. FOLLOWING INFO
REFERS TO RADIOACTIVE MATL: INHAL: VERY SM FRACTION OF SODIUM
IODIDE I 131 MAY BREAK DOWN & EMIT RADIOACTIVE FUMES CNTNG I 131.
NOT EXPECTED TO BE HEALTH HAZARD VIA INHAL . INGEST: MAY CAUSE
ASYMPTOMATIC PHYSIOLOGICAL UPTAKE BY THYROID GLAND/OTHER TISSUES.
SKIN CONT: NOT EXPECTED TO PRDCE ANY ACUTE ADVERSE HLTH EFTS. EYE
CONT: NO ADVERSE EFT EXPECTED, BUT MAY CAUSE (EF TS OF OVEREXP)
Effects of Overexposure:HLTH HAZ: MECHANICAL IRRITATION. CHRONIC: THE
HEALTH RISKS ASSOCIATED WITH CHRONIC RADIATION EXPOSURE (CANCER,
LEUKEMIA, GENETIC & TERATOGENIC EFTS) ARE BELIEVED TO INVOLVE
LEVELS OF RADIATION EXPOSUR E WHICH ARE MUCH HIGHER THAT THOSE
PERMITTED OCCUPATIONALLY.
Medical Cond Aggravated by Exposure:NO INFORMATION FOUND.

First Aid:INHAL: NOTIFY RADIA SFTY PERSONNEL IMMED. THE AMT OF MATL
INHALED SHOULD BE ASSESSED & DOCUMENTED. INGEST: NOTIFY RADIA SFTY
PERSONNEL IMMED. THE AMT OF I 131 IN THYROID GLAND SHOULD BE
ASSESSED & DOC UMENTED. A THYROID BLOCKING AGENT MAY BE WARRANTED &
ADMINISTERED UNDER DIRECTION OF PHYS. SKIN: WASH AREA THOROUGHLY
W/SOAP & WATER UNTIL NO MORE RADIOACTIVITY CAN BE REMOVED. ALWAYS
BLOT DRY. DO NOT ABRADE SKIN. NOTIFY RADIA SFTY PERSONNEL. EYE:
WASH W/WATER FOR AT LST 15 MINUTES OR UNTIL NO MORE RADIOACTIVITY
CAN BE REMOVED. NOTIFY RADIA SFTY PERSONNEL.

Extinguishing Media:NOT A FLAMMABLE MATERIAL. USE ANY MEANS SUITABLE
FOR EXTINGUISHING SURROUNDING FIRE.
Fire Fighting Procedures:USE NIOSH APPROVED SCBA & FULL PROTECTIVE
EQUIPMENT .
Unusual Fire/Explosion Hazard:NOT CONSIDERED TO BE A FIRE OR EXPLOSION
HAZARD.

Spill Release Procedures:IF PROD IS RECEIVED IN LEAKING CNDTN/ANY
LOSS/RELEASE OF RADIOACTIVE CONTENTS OCCURS, NOTIFY YOUR RADIATION
SAFETY DEPARTMENT & MALLINCKRODT AT (314) 770-7800. ALL CLEANUP
OPERATIONS SHOULD BE PERFORM ED ACCORDING TO STD OPERATING
PROCEDURES (SOPS) ESTABLISHED TO YOUR FACILITY & BY NRC/OTHER
APPLIC LOCAL, STATE OR FEDERAL REGULATIONS.

Handling and Storage Precautions:STORE AT 15C TO 30C. HNDLG TIME SHOULD
BE KEPT TO MINIMUM & APPROPRIATE SHIELDING SHOULD BE USED. HANDLING
DEVICES SUCH AS SYRINGE SHIELDS & TONGS SHOULD BE USED.
Other Precautions:STORAGE & DISP OF PROD SHOULD BE CONTROLLED IN MANNER
WHICH IS IN COMPLIANCE W/APPROP REGS OF FEDERAL/STATE GOVERNMENT
AGENCY AUTHORIZED TO LICENSE USE OF THIS RADIONUCLIDE. CAUTION!
RADIOACTIVE MATL. READ PACKAGE INSERT PRIOR TO USE. PROMPTLY
REMOVE ANY CONTAMINATION FROM SKIN, EYES/CLTHG. RADIOACT IVE DRUGS
(SUPDAT)

Respiratory Protection:NOT EXPECTED TO REQUIRE PERSONAL RESPIRATOR
USAGE. NIOSH APPROVED RESPIRATOR APPROPRIATE FOR EXPOSURE OF
CONCERN .
Ventilation:PROPERLY SEALED CONTAINERS ARE NOT EXPECTED TO REQUIRE ANY
SPECIAL VENTILATION.
Protective Gloves:DISPOSABLE PLASTIC, LATEX, OR RUBBER GLOVES.
Eye Protection:ANSI APPROVED CHEMICAL WORKERS GOGGLES .
Other Protective Equipment:EYE WASH & DELUGE SHOWER MEETING ANSI DESIGN
CRITERIA . LABCOAT.
Work Hygienic Practices:NO SMOKING, EATING, OR DRINKING SHOULD BE
ALLOWED IN ANY AREA WHERE RADIOACTIVE MATERIALS ARE HANDLED OR
STORED.
Supplemental Safety and Health
WASTE DISP METH: BIOHAZARD & DISPOSED OF ACCORDINGLY. IF NOT
RADIOACTIVE/BIOHAZARD, WASTE SODIUM IODIDE I 131 ORAL THERAPEUTIC
SOLN IS CONSIDERED NON-HAZ. CONSULT LOCAL, STATE & FEDERAL REGS FOR
PROPE R DISP. OTHER PREC: MUST BE HNDLD BY QUALIFIED PERSONNEL IN
CONFORMITY W/REGS APPROP TO GOVERNMENT AGENCY (OTHER INFO)

Boiling Pt:=100.C, 212.F
Melt/Freeze Pt:=0.C, 32.F
Evaporation Rate & Reference:NO INFORMATION FOUND.
Solubility in Water:SOLUBLE
Appearance and Odor:CLEAR, COLORLESS LIQUID IN A 10 ML FRENCH-SQUARE,
SCREW-CAP VIAL. ODORLESS.

Stability Indicator/Materials to Avoid:YES
NO INFORMATION FOUND
Stability Condition to Avoid:STABLE UNDER ORDINARY CONDITIONS OF USE &
STORAGE. A VERY SMALL FRACTION OF SODIUM LODIDE I 131 SOLN MAY
BREAK DOWN & EMIT RADIOCATIVE FUMES CONTAINING I 131.
Hazardous Decomposition Products:MAY EMIT RADIOACTIVE FUMES CONTAINING
WHEN HEATED TO DECOMPOSITION.

Waste Disposal Methods:SODIUM IODIDE I 131 ORAL THERAPEUTIC SOLN IS
RADIOACTIVE WASTE UNTIL ACTIVITY HAS DECAYED TO NONDETECTABLE
LEVELS. RADIOACTIVE WASTE MUST BE HNDLD I/A/W PROCEDURES
ESTABLISHED BY YOUR RADIATION SFTY O FFICER, NRC & OTHER APPLIC
REGS. IF MED WASTE IS INVOLVED, SUCH AS BLOOD, BLOOD PRODS/SHARPS,
WASTE MUST BE HNDLD AS (SUPDAT)

Toxicological Information:IT IS WIDELY ACCEPTED BY SCIENTIFIC COMMUNITY
THAT EXPOSURE TO SUFFICIENT QTYS OF IONIZING RADIA CAN POTENTIALLY
CAUSE HARMFUL BIOLOGICAL EFTS WHICH INCL CANCER, LEUKEMIA, &
GENETIC & TERATOGENIC EFTS . THE UPTAKE OF I 131 CAN RESULT IN
SLIGHT TO TOTAL THYROID DYSFUNCTION. FOR DETAILED TOXICOLOGICAL
INFORMATION ON SPECIFIC COMPONENTS, WRITE TO THE ADDRESS LISTED IN
CHEMICAL PRODUCT & COMPANY IDENTI FICATION- ATTN: REGULATORY
COMPLIANCE DEPARTMENT.

Disclaimer (provided with this information by the compiling agencies):
This information is formulated for use by elements of the Department
of Defense. The United States of America in no manner whatsoever,
expressly or implied, warrants this information to be accurate and
disclaims all liability for its use. Any person utilizing this
document should seek competent professional advice to verify and
assume responsibility for the suitability of this information to their
particular situation.

Ecological:BECAUSE THIS PRODUCT IS INTENDED FOR USE BY HOSPITAL OR
CLINIC PATIENTS, IT IS EXPECTED TO BE TREATED BY STANDARD
WASTEWATER TREATMENT FACILITIES WITH NO ADVERSE ENVIRONMENTAL
IMPACTS.

Transport Information:DOT (DEPARTMENT OF TRANSPORTATION): PROPER
SHIPPING NAME: RADIOACTIVE MATERIAL, N.O.S. HAZARD CLASS: 7.
IDENTIFICATION NUMBER: UN2982. RQ: SHIPMENTS OF 10 MCI OR MORE PER
PACKAGE MUST HAVE "RQ" MARKED ON THE PACKAGE EXTERIOR AND ON THE
SHIPPING PAPERS.

SARA Title III Information:302 EXTREMELY HAZARDOUS SUBSTANCES: NONE.
311/312 HAZARD CATEGORIES: CHRONIC. 313 TOXIC SUBSTANCES SUBJECT TO
ANNUAL RELEASE REPORTING REQUIREMENTS. NONE.
Federal Regulatory Information:OSHA HAZARD COMMUNICATION: THIS PRODUCT
IS CONSIDERED HAZARDOUS UNDER THE OSHA HAZARD COMMUNICATION
STANDARD (29 CFR 1910.1200) CERCLA REPORTABLE QUANTITIES: I 131 =
0.01 CI (3.7 E 8 BQ); SODIUM PHOSP HATE, DIBASIC = 5000 LBS; SODIUM
BISULFITE = 5000 LBS. RELEASES TO AIR, LAND/WATER OF THESE
HAZARDOUS SUBSTANCES WHICH EXCEED THE REPORTABLE QUANTITY (RQ) MUST
BE REPORTED TO NATIONAL REPONSE CENTER A T 800-424-8802. RCRA
HAZARDOUS WASTE STATUS: NON-HAZARDOUS (SEE DISPOSAL CONSIDERATION
SECTION FOR A DDITIONAL DETAILS).
State Regulatory Information:CALIFORNIA PROPOSITION 65 WARNING: THIS
PRODUCT CONTAINS A SUBSTANCE KNOWN TO THE STATE OF CALIFORNIA TO
CAUSE CANCER AND REPRODUCTIVE.